Predictors of Cognitive Behavioral Therapy for Insomnia in Older Adults.

Behav Sleep MedApr 17, 2026 (epub)
Clinical ResearchGeriatricsPsychiatry

Abbas Tabatabaei, Eryen Nelson, Allison Glaser et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated predictors of success in Cognitive Behavioral Therapy for Insomnia (CBT-I) among 96 older adults with insomnia. Results showed significant reductions in insomnia severity, with Insomnia Severity Index (ISI) scores decreasing after six weeks (Z = 8.3, p < .001) and remaining improved at 12 months (Z = 8, p < .001).

Key findings

  • ISI scores decreased significantly after six weeks of CBT-I (Z = 8.3, p < .001).
  • ISI scores remained significantly improved at the 12-month follow-up (Z = 8, p < .001).
  • Higher baseline sleep self-efficacy was associated with lower ISI scores immediately after CBT-I (β = -0.03, p < .02).
  • Lower depression severity was linked to lower ISI scores immediately after CBT-I (β = 0.06, p = .04).

Why it matters

Understanding predictors of CBT-I success can help clinicians tailor treatment plans for older adults with insomnia, potentially improving outcomes and ensuring more effective use of non-pharmacological interventions.

Source

PubMed · PMID 41994939

Published in Behav Sleep Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.